Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

ABSTRACT:

Context

The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.

Objective

To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.

Design, setting, and patients

Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer. The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%). Last follow-up was in December 2008; inclusion criteria were hormone rec

SUBMITTER: Schroth W 

PROVIDER: S-EPMC3909953 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature